A compound of formula (I) is described. The compounds can be used in the manufacture of a medicament for treating or preventing mood disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression, anorexia, weight loss, insomnia, early morning waking and psychomotor retardation, atypical depression (or reactive depression), including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression ; or bipolar disorders or manic depression; anxiety disorders, specific phobias, stress disorders; borderline personality disorder; schizophrenia, psychotic disorders, psychotic disorders, autistic disorder, delerium, dementia, and other cognitive or neurodegenerative disorders, such as Parkinson's disease, Huntington's disease, Alzheimer's disease, memory disorder and vascular dementia, Pick's disease, Creutzfeldt-Jakob disease; movement disorders such as akinesias, dyskinesias; extra-pyramidal movement disorders such as medication-induced movement disorders; substance related disorders arising from the use of alcohol, amphetamines, caffeine, cannabis, cocaine, hallucinogens, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, and anxiolytics; epilepsy; Down's syndrome; pain and migraine; multiple sclerosis and amylolateral sclerosis, peripheral neuropathy, respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis, inflammatory diseases; HIV infections; allergies; ophthalmic diseases; cutaneous diseases; neoplasms, including breast tumours, gastric carcinomas, gastriclymphomas, neuroganglioblastomas and small cell carcinomas gastrointestinal disorders, adverse immunological reactions such as rejection of transplanted tissues; disorders of bladder function; fibrosing and collagen diseases; blood flow disorders caused by vasodilation and vasospastic diseases such as angina and Reynaud's disease; angiogenesis; cardiovascular disorders; eating disorders, such as anorexia nervosa and bulimia nervosa ; attention deficit hyperactivity disorder; chronic fatigue syndrome; sexual dysfunctions including premature ejaculation and male erectile dysfunction; premenstrual syndrome and premenstrual dysphoric disorder; fibromyalgia; and rheumatic diseases such as fibrositis. Also described are compounds of formula (II). In the compounds of formula (I) and (II) Q is C=S or C=O; Y is N and Z is CH or Y is CH and Z is N; W is a 1 or 2 carbon linking group. In formula (I) B is absent methylene or ethylene, G is NH(CH2)q, S(CH2)q or O(CH2)q wherein q is 0 or 1, with the proviso that when q is 0, G is NH, S or O and p is 0, 1 or 2.
Benzoamide piperidine containing compounds and related compounds